5 articles
Dr Reddy's shares fell nearly 7% as brokerages cut forecasts due to weak margins and semaglutide supply disruptions lasting until late October. Analysts indicate recovery depends on supply resumption
Dr Reddy's Q1 profit plunged 68.7% to 4.44 billion rupees due to semaglutide inventory costs stemming from an active ingredient impurity. Revenue dropped 5.5% amidst pricing pressures and market compe
Indian shares are poised to fall as Brent crude surged to a five-week high amid escalating Middle East conflicts. Investors await quarterly results from key firms including Dr Reddy's and Nestle while
Dr Reddy's shares fell after halting semaglutide injections due to an API impurity. Analysts downgraded earnings forecasts, warning the supply disruption could erode the company's market advantage.
Alembic Pharmaceuticals posted a 29.2% rise in fourth-quarter profit to 2.03 billion rupees, driven by strong U.S. generics demand. Overall revenue increased 4.4%, contrasting with weaker results from
ChemBrief